Global Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market

Publish Date: May 2020

Report Code: VMR2076A

Publisher: Verified Market Research

Single User License: $3950

Explore Our Services

Already a member? Login here.

Report Highlights

Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market Size And Forecast

According To Verified Market Research, Global Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market is growing at a faster pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2019 to 2026.

Global Acute Bacterial Skin and Skin Structure Infection (ABSSSI) Market Outlook

Increasing research and development activities by pharmaceutical and biopharmaceutical companies to develop new products and novel treatment is the major driver responsible for the growth of the global ABSSSI market. For instance, in February 2019, Paratek Pharmaceuticals Inc., launched NUZYRA intravenous and oral antibiotics in the treatment of ABSSSI. Moreover, in 2018, Fresenius Kabi received US FDA approval for a new drug application of daptomycin. Besides, an increasing number of ambulatory patients seeking treatment for skin and skin structure infections will further be expected to fuel the market growth. However, the stringent regulatory policies by government bodies, patent expiration, and increasing incidence of resistant strains of causative agents are the factors that might hamper the market growth. 

Global Acute Bacterial Skin and Skin Structure Infection (ABSSSI) Market Competitive Landscape 

The Global Acute Bacterial Skin and Skin Structure Infection (ABSSSI) Market study report will provide valuable insight with an emphasis on the global market including some of the major players such as Glenmark Pharmaceuticals Ltd, Fresenius SE & Co. KGaA, Teva Pharmaceutical Industries Ltd, Melinta Therapeutics, Inc., Sandoz Inc. (a subsidiary of Novartis), Paratek Pharmaceuticals, Inc., Allergan plc, Merck & Co., Inc., Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Ltd.), and Cadila Healthcare Ltd.

Verified Market Research has been providing Research Reports, with up to date information, and in-depth analysis, for several years now, to individuals and companies alike that are looking for accurate Research Data. It has large database which includes the latest content from renowned authors and publications worldwide. It also provides customized Data and Reports according to the need of the client.

Become A Member

BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.

Find Out More

Custom Consulting

BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.

Customize Now

Scorecard

The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.

Find Out More

Innovation Spotlight

Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.

Find Out More
Global Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market